---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-23-000791"
form_type: "8-K"
ticker: "LEXX"
cik: "0001348362"
company_name: "Lexaria Bioscience Corp."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T06:04:13.998135+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Lexaria Bioscience shareholders reelect all 6 director nominees and approve all proposals at annual meeting

## Summary
- All six director nominees elected: Bunka (96.5%), Docherty (96.3%), Baxter (74.3%), McKechnie (95.7%), Reese (96.2%), Turkel (97.6%).
- Stock option repricing approved with 68.9% of votes cast (1,529,271 for; 677,686 against).
- Amendment to Incentive Equity Plan (max shares) approved with 88.6%; evergreen formula addition approved with 63.1%.
- Appointment of Malone Bailey LLP as auditors ratified with 96.4% (3,249,199 for).
- Ratification of directors' past actions approved with 90.4%.

## SEC filing metadata
- accession: 0001640334-23-000791
- form_type: 8-K
- ticker: LEXX
- cik: 0001348362
- company_name: Lexaria Bioscience Corp.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348362/000164033423000791/0001640334-23-000791-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348362/000164033423000791/lxrp_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-23-000791
- JSON: https://secwatch.observer/filing/0001640334-23-000791.json
- Plain text: https://secwatch.observer/filing/0001640334-23-000791.txt

## Key facts
- Shareholder Votes
  Lexaria Bioscience Corp. shareholders approved To Appoint Malone Bailey LLP as Auditors at the 2023-05-09 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-05-09
  source text: To Appoint Malone Bailey LLP as Auditors 3,249,199 105,067 17,758 96.4%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348362/000164033423000791/0001640334-23-000791-index.htm
- Shareholder Votes
  Lexaria Bioscience Corp. shareholders approved To Approve the Stock Option Repricing at the 2023-05-09 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2023-05-09
  source text: To Approve the Stock Option Repricing 1,529,271 677,686 12,429 1,152,638 68.9%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348362/000164033423000791/0001640334-23-000791-index.htm
- Shareholder Votes
  Lexaria Bioscience Corp. shareholders approved To Ratify the lawful actions of the directors for the past year at the 2023-05-09 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-05-09
  source text: To Ratify the lawful actions of the directors for the past year 2,005,926 156,382 57,145 1,152,571 90.4%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348362/000164033423000791/0001640334-23-000791-index.htm
- Shareholder Votes
  Lexaria Bioscience Corp. shareholders approved To Approve the Amendment to the Maxim Number of Shares Issuable pursuant to the Incentive Equity Plan at the 2023-05-09 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2023-05-09
  source text: To Approve the Amendment to the Maxim Number of Shares Issuable pursuant to the Incentive Equity Plan 1,965,779 249,519 4,155 1,152,571 88.6%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348362/000164033423000791/0001640334-23-000791-index.htm
- Shareholder Votes
  Lexaria Bioscience Corp. shareholders approved Election of Directors at the 2023-05-09 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-05-09
  source text: To Elect Chris Bunka as a director 2,141,964 77,489 1,152,571 96.5% To Elect John Docherty as a director 2,137,546 81,907 1,152,571 96.3% To Elect Nicholas Baxter as a director 1,648,288 571,165 1,152,571 74.3% To Elect Ted McKechnie as a director 2,123,869 95,584 1,152,571 95.7% To Elect Albert Reese Jr. as a director 2,134,837 84,683 1,152,504 96.2% To Elect Dr. Catherine Turkel as a director 2,165,426 54,027 1,152,571 97.6%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348362/000164033423000791/0001640334-23-000791-index.htm
- Shareholder Votes
  Lexaria Bioscience Corp. shareholders approved To Approve the Addition of an Evergreen Formula to the Incentive Equity Plan at the 2023-05-09 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2023-05-09
  source text: To Approve the Addition of an Evergreen Formula to the Incentive Equity Plan 1,400,723 709,940 108,790 1,152,571 63.1%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348362/000164033423000791/0001640334-23-000791-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.